Slow-release oral morphine: Difference between revisions

From IDWiki
No edit summary
()
 
Line 1: Line 1:
== Background ==
==Background==


* Morphine sulphate sustained release capsules (Kadian)
*Morphine sulphate sustained release capsules (Kadian)
** Beads contain both immediate release and slow release morphine
**Beads contain both immediate release and slow release morphine
** IR released by stomach acid and SR released in bowels at higher pH
**IR released by stomach acid and SR released in bowels at higher pH
** Capsules themselves may pass in the stool
**Capsules themselves may pass in the stool
* Full opioid agonist
*Full opioid agonist
* Approved for chronic pain, but used off-label for [[opioid use disorder]]
*Approved for chronic pain, but used off-label for [[opioid use disorder]]
* Appears likely to be equivalent to [[methadone]], but higher patient satisfaction
*Appears likely to be equivalent to [[methadone]], but higher patient satisfaction
* Peak plasma level 8.5 to 10 hours
*Peak plasma level 8.5 to 10 hours
* Elimination half life 11 13 hours
*Elimination half life 11 13 hours


==Dosing==
==Dosing==


* For daily dispensed, often opened and sprinkled on apple sauce or yoghurt, or water
*For daily dispensed, often opened and sprinkled on apple sauce or yoghurt, or water
* Capsule sizes include 10, 20, 50, and 100 mg
*Capsule sizes include 10, 20, 50, and 100 mg
* Specify on the prescription if it is being used for OUD or chronic pain
*Specify on the prescription if it is being used for OUD or chronic pain


===BC OUD Guidelines===
===BC OUD Guidelines===
Line 58: Line 58:
|}
|}


=== Off-Guideline ===
===Off-Guideline===


* For induction from methadone or non-methadone opioids with high opioid tolerance
*For induction from methadone or non-methadone opioids with high opioid tolerance
* Start at 200 to 300 mg, then increase by 100 to 150 q48h
*Start at 200 to 300 mg, then increase by 100 to 150 q48h
* Missed days
*Missed days
** 1: full
**1: full
** 2: 50% reduction
**2: 50% reduction
** 3: 75% reduction or resume at initiation dose
**3: 75% reduction or resume at initiation dose
** 4: resume at initiation dose
**4: resume at initiation dose


=== Carries ===
===Carries===


* Per guidelines, doses should be indefinitely witness ingestion
*Per guidelines, doses should be indefinitely witness ingestion
* However, may be reasonable to do same for [[methadone]]
*However, may be reasonable to do same for [[methadone]]
** No carrier x 8 weeks, then one carry per week every month with weekly urine drug screens
**No carrier x 8 weeks, then one carry per week every month with weekly urine drug screens


=== Switch to Methadone ===
===Switch to Methadone===


* Must stop SROM and start [[methadone]] titration from 30 mg
*Must stop SROM and start [[methadone]] titration from 30 mg


=== Switch to M-Eslon ===
===Switch to M-Eslon===


* Split SROM dose for BID M-Eslon
*Split SROM dose for BID M-Eslon
* Dosages include 10, 15, 30, 60, 100, and 200 mg
*Dosages include 10, 15, 30, 60, 100, and 200 mg


== Safety ==
==Safety==


* Adverse effects include GI cramping, abdominal pain, headache, hyperhidrosis, constipation, frequent urination, nausea/vomiting, and insomnia
*Adverse effects include GI cramping, abdominal pain, headache, hyperhidrosis, constipation, frequent urination, nausea/vomiting, and insomnia
* Risk of respiratory depression and other forms of [[opioid toxicity]]
*Risk of respiratory depression and other forms of [[opioid toxicity]]
* Safe in pregnancy
*Safe in pregnancy
** Small RCT suggests no difference from [[methadone]] in neonatal outcomes but possibly lower unprescribed drug use in SROM
**Small RCT suggests no difference from [[methadone]] in neonatal outcomes but possibly lower unprescribed drug use in SROM


=== Contraindications ===
===Contraindications===


* Hypersensitivity to morphine
*Hypersensitivity to morphine
* Respiratory
*Respiratory
** Significant respiratory depression
**Significant respiratory depression
** Acute or severe bronchial asthma
**Acute or severe bronchial [[asthma]]
** Severe respiratory compromise or obstructive disease
**Severe respiratory compromise or obstructive disease
* Gastrointestinal
*Gastrointestinal
** Known or suspected paralytic ileus
**Known or suspected paralytic [[ileus]]
** Short gut syndrome of transit time abnormalities
**[[Short gut syndrome]] of transit time abnormalities
*Alcohol use, including intoxication and [[Alcohol withdrawal|withdrawal]]
* Alcohol use
* MAOI use within 14 days
*MAOI use within 14 days


[[Category:Medications]]
[[Category:Medications]]

Latest revision as of 18:37, 5 March 2021

Background

  • Morphine sulphate sustained release capsules (Kadian)
    • Beads contain both immediate release and slow release morphine
    • IR released by stomach acid and SR released in bowels at higher pH
    • Capsules themselves may pass in the stool
  • Full opioid agonist
  • Approved for chronic pain, but used off-label for opioid use disorder
  • Appears likely to be equivalent to methadone, but higher patient satisfaction
  • Peak plasma level 8.5 to 10 hours
  • Elimination half life 11 13 hours

Dosing

  • For daily dispensed, often opened and sprinkled on apple sauce or yoghurt, or water
  • Capsule sizes include 10, 20, 50, and 100 mg
  • Specify on the prescription if it is being used for OUD or chronic pain

BC OUD Guidelines

  • Eligible in age >19 and switching from methadone or actively using opioids
  • When transitioning from methadone, the eventual dose will usually be 8 times higher, but generally should start with a 4-times higher dose to be safe
    • Increase by 30 to 60 mg daily q48h
  • For other opioids, start with dose of 30 to 60 mg
    • Increase doses q48h based on withdrawal symptoms
  • Average stable doses are 60 to 1200 mg daily

Missed Doses

Number missed Action
1 no change
2 40% reduction
3 60% reduction
4 80% reduction
5 re-initiate

St. Michael's Protocol

Day Slow-release morphine Instant-release morphine
1 200-300 mg 30-50 mg po q2h while awake + 30-50 mg po q3h prn
2 SR dose from Day 1 + 50% of IR dose from Day 3 30-50 mg po q2h while awake + 30-50 mg po q3h prn
3 SR dose from Day 2 30-50 mg po q3h prn
4 SR dose from Day 3 + 50% of IR dose from Day 3 30-50 mg po q3h prn
5 SR dose from Day 4 30-50 mg po q3h prn
6 SR dose from Day 5 + 50% of IR dose from Day 5 30-50 mg po q3h prn

Off-Guideline

  • For induction from methadone or non-methadone opioids with high opioid tolerance
  • Start at 200 to 300 mg, then increase by 100 to 150 q48h
  • Missed days
    • 1: full
    • 2: 50% reduction
    • 3: 75% reduction or resume at initiation dose
    • 4: resume at initiation dose

Carries

  • Per guidelines, doses should be indefinitely witness ingestion
  • However, may be reasonable to do same for methadone
    • No carrier x 8 weeks, then one carry per week every month with weekly urine drug screens

Switch to Methadone

  • Must stop SROM and start methadone titration from 30 mg

Switch to M-Eslon

  • Split SROM dose for BID M-Eslon
  • Dosages include 10, 15, 30, 60, 100, and 200 mg

Safety

  • Adverse effects include GI cramping, abdominal pain, headache, hyperhidrosis, constipation, frequent urination, nausea/vomiting, and insomnia
  • Risk of respiratory depression and other forms of opioid toxicity
  • Safe in pregnancy
    • Small RCT suggests no difference from methadone in neonatal outcomes but possibly lower unprescribed drug use in SROM

Contraindications

  • Hypersensitivity to morphine
  • Respiratory
    • Significant respiratory depression
    • Acute or severe bronchial asthma
    • Severe respiratory compromise or obstructive disease
  • Gastrointestinal
  • Alcohol use, including intoxication and withdrawal
  • MAOI use within 14 days